Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Colaizzo

Pediatrics Jupiter, FL Medical Doctor

NPI 1821023334 CMS profile 870261

6650 W Indiantown Rd, Suite 110, Jupiter, FL 33458

Open in the dashboard

General payments

$2,243

120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Colaizzo of Jupiter, FL is reported in the CMS Open Payments database as having received $2,243 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $637 28
2024 General $350 18
2023 General $353 23
2022 General $144 8
2021 General $339 19
2020 General $318 18
2019 General $102 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Colaizzo
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Philip Colaizzo were reported at $637. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Philip Colaizzo Pediatrics median Middle half National median
2019 $102 $86 $31–$183 $163
2020 $318 $49 $22–$110 $114
2021 $339 $68 $27–$158 $132
2022 $144 $77 $30–$173 $149
2023 $353 $88 $33–$190 $160
2024 $350 $94 $34–$206 $164
2025 $637 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Corium, Inc. $376 24 payments
  2. Supernus Pharmaceuticals, Inc. $334 19 payments
  3. Collegium Pharmaceutical, Inc. $289 12 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $177 7 payments
  5. Ironshore Pharmaceuticals Inc. $173 10 payments
  6. Adlon Therapeutics L.P. $161 10 payments
  7. Neurelis, Inc. $144 3 payments
  8. Cranial Technologies, Inc $119 8 payments
  9. Tris Pharma Inc $93 6 payments
  10. GlaxoSmithKline, LLC. $88 5 payments
  11. Other $290 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,243 120 payments
Products named General payments · program years 2019–2025
  1. Azstarys $376 24 payments
  2. Jornay PM Adhd $289 12 payments
  3. Qelbree Viloxazine Hydrochloride $200 6 payments
  4. VYVANSE $173 7 payments
  5. ADHANSIA XR $161 10 payments
  6. VALTOCO $144 3 payments
  7. QELBREE Psychology $134 13 payments
  8. Doc Band $119 8 payments
  9. BEXSERO $88 5 payments
  10. JORNAY PM Central Nervous Stimulant ADHD $85 5 payments
  11. Other $649 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

138

Median for Pediatric Medicine: 38

Drug cost

$7,064

Median for Pediatric Medicine: $2,769

Branded share of claims

19.6%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Risperidone Generic 20 $3,066
Desmopressin Acetate Generic 12 $1,242
Buspirone Hcl Generic 16 $740
Lorazepam Intensol Lorazepam Brand 12 $582
Lactulose Generic 12 $567
Doxycycline Hyclate Generic 15 $307
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 15 $285
Quetiapine Fumarate Generic 12 $174
Sertraline Hcl Generic 12 $58
Azithromycin Generic 12 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VALTOCO
  • Neurelis, Inc. $111
$111 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $72
$72 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $51
$51 — —
Azstarys
  • Corium, Inc. $29
$29 — —
BEXSERO
  • GlaxoSmithKline, LLC. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record